Bimagrumab
Eli Lilly
Activin type II receptor antibody investigated with incretin therapy.
Selected study results
Bimagrumab + semaglutide vs semaglutideWeight changeBody weight decreased 17.8 kg · 48 weeks · Phase 2
Weight change · 48 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity without diabetes · Bimagrumab 30 mg/kg IV + semaglutide 2.4 mg vs semaglutide 2.4 mg · Trial N=507 · Least-squares mean kilograms; selected trial arms, not a cross-trial comparison. Results & methods ↗
Bimagrumab monotherapy · body composition with type 2 diabetesMean total body-fat mass changeFat mass decreased 20.5% · 48 weeks · Phase 2
Mean total body-fat mass change · 48 weeks
Study focus: Body composition with type 2 diabetes
Adults with type 2 diabetes and BMI 28–40 kg/m² · 10 mg/kg IV, maximum 1,200 mg, every four weeks · Trial N=75 · Least-squares means; analysis restricted to participants completing treatment. Results & methods ↗ · Publication ↗
- Other endpoints · same studyBody weight changed by −6.5% versus −0.8%; lean mass by +3.6% versus −0.8%; HbA1c by −0.76 versus +0.04 percentage points.
Fat-mass change is not body-weight change. Only 58 of 75 participants completed 48 weeks; the completer analysis limits interpretation.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Body-composition and other targets appear alongside hormone pathways in this overview.
Explore the hormone anatomy ↗Obesity stage by formulation
Latest: Phase 2 semaglutide combination trial published.
Next: Results from the completed Phase 2 bimagrumab/tirzepatide study NCT06643728; the registry lists no posted results.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies2 records
Bimagrumab + tirzepatide · completed Phase 2
Weight management / body compositionSeparate Phase 2 combination study completed October 27, 2026; 252 actual participants and a week-24 body-weight primary endpoint. No registry results are posted. This is distinct from withdrawn, zero-enrollment NCT06901349.
Bimagrumab with or without semaglutide
Body composition and weight management507-adult randomized obesity study; bimagrumab monotherapy, semaglutide, and combination groups are arms within the same trial.
Related conditions and outcomes
Phase 2 studies2 records
Bimagrumab + tirzepatide
Combination developmentSeparate combination protocol withdrawn before enrollment (zero participants), for strategic business reasons; distinct from completed NCT06643728.
Bimagrumab monotherapy in type 2 diabetes and obesity
Body composition with type 2 diabetesPublished 48-week study of fat mass, lean mass, weight and glycemic outcomes; distinct from the later combination trial.
